Searched for
USFDA NATCO PHARMA
NATCO Pharma receives FDA Establishment Inspection Report for Visakhapatnam plantNATCO Pharma announced receiving an Establishment Inspection Report from the US FDA for its FDF Unit. The inspection took place in Vishakha...
Alembic Pharma partner NATCO gets USFDA tentative nod for generic Olaparib tablets; US market size at USD 1.4 bnAlembic Pharmaceuticals and NATCO Pharma received tentative USFDA approval for generic Olaparib tablets. This approval is for a cancer drug...
Natco Pharma, 3 other pharma stocks decline up to 2.5% after important inspections at their units. Do you own?Indian pharmaceutical stocks, including Lupin, Shilpa Medicare, and Natco Pharma, are under scrutiny following recent USFDA inspections at ...
USFDA issues Form 483 with 7 observations to Natco's pharma Hyderabad divisionNatco Pharma announced that its Hyderabad-based pharma division received a Form 483 with seven observations from the USFDA following an ins...
Natco Pharma gets warning letter from USFDA for Telangana plantNatco Pharma, a pharmaceutical company, received a warning letter from the USFDA regarding its manufacturing plant in Telangana. This came ...
Natco Pharma's marketing partner gets USFDA nod for anti-cancer drugNatco Pharma said based on the ANDA filing date, the company believes that it is eligible for 180 days of sole generic marketing exclusivit...
Eli Lilly inks pacts for Baricitinib with Sun Pharma, Cipla, Lupin for COVID-19 treatment in IndiaAs the threat of compulsory licence (CL) looms over big pharma in India, companies are rushing in to sign voluntary licensing agreements th...
Natco's marketing partner gets USFDA nod for cancer treatment drug"Breckenridge Pharmaceutical Inc (BPI) has received final approval for its abbreviated new drug application (ANDA) for Everolimus tablets f...
Natco Pharma's marketing partner gets USFDA nod for cancer treatment drug"Breckenridge Pharmaceutical Inc. has received final approval for its abbreviated new drug application (ANDA) for Pomalidomide Capsules fro...
Natco Pharma gets USFDA approval for Visakhapatnam facilityHyderabad-based Natco Pharma Ltd on Tuesday said it has received the final approval from the US health regulator for its first supplemental...
USFDA issues 6 observations to Natco Pharma's API facility near HyderabadThe United States Food and Drug Administration (USFDA) conducted inspection at Kothur facility between August 5-9, 2019.
USFDA issues 9 observations to Natco Pharma's Kothur facility"At the end of the inspection, the facility received 9 observations, with no repeat observations and mostly procedural in nature," Natco Ph...
USFDA makes 6 observations at Natco Pharma's Kothur facilityNatco Pharma said it will provide due justifications and corrective action plan within next 15 working days to the address the USFDA observ...
Natco Pharma gets USFDA nod for Armodafinil tabletsNatco Pharma has received final approval from the US Food and Drug Administration (USFDA) for generic version of Armodafinil tablets.
Natco Pharma gets USFDA nod for generic Budesonide capsulesThe company has received "final approval of abbreviated new drug application from the US Food and Drug Administration for generic version o...
Natco Pharma gets EIR from USFDA for Kothur facilityKothur facility predominantly caters to regulated international markets. EIR is given after the completion of the inspection by the USFDA.
Natco will out-license molecules to big pharma: Amit Rajan, Director, Celogen LifeAmit Rajan, Director, Celogen Life says that Micro Labs will quickly come out of the FDA and midcap space as they have a good R&D pipeline.
USFDA observations on 2 units not to impact products: Natco"The company has received 483 observations for both facilities and believes them to be of minor in nature," a statement said.
Natco Pharma's US partner Mylan files application with USFDANatco Pharma's marketing partner Mylan Inc has filed an application with the US health regulator for generic Sorafenib tablets used mainly ...
Natco Pharma's partner Mylan Inc files ANDA for generic CopaxoneAccording to IMS health, Copaxone 40 mg/mL had US sales of nearly USD 411.5 million for the 12 months ending June 30, 2014, it added.